Oruka Therapeutics Shares Fall 5% After Week 28 ORKA-001 Trial Data
Oruka Therapeutics (NASDAQ:ORKA) shares dropped 5% after reporting Week 28 data from its EVERLAST-A Phase 2a trial for ORKA-001 in treating plaque psoriasis. The trial showed a PASI 100 response rate of 71.4% and a PASI 90 rate of 87.3%. The company plans to release 52-week data in December 2026.
How this was made
The 30-second read
Why it matters
The Week 28 data provides the first efficacy update beyond Week 16, indicating continued response improvement.
Market read
New trial data is a primary catalyst for ORKA stock, potentially affecting peer valuations.
What to watch
Upcoming 52‑week data and Phase 2b results could significantly alter outlook.
Background
Oruka Therapeutics is a Nasdaq‑listed biotech developing IL‑23p19 monoclonal antibodies for plaque psoriasis.
Ticker impact
Oruka Therapeutics reported new Week 28 Phase 2a trial results for ORKA-001, showing PASI 100 response of 71.4% and PASI 90 of 87.3%, causing a 5% share decline.
Potential further 2-3% decline intraday as investors reassess valuation.
Trial data is new and material for a biotech, but the modest improvement over prior week and safety profile lead to cautious reaction.
Market effects
May influence peer biotech valuations in IL-23 inhibitor space.
Limited to US biotech sector.
Low global impact beyond specialty dermatology market.
Counterpoint
Data may be overemphasized; long-term efficacy and commercial potential remain uncertain.
Key entities
- CompanyOruka Therapeutics
Biotech firm developing ORKA-001 for psoriasis.
